(Total Views: 632)
Posted On: 11/11/2022 5:20:25 AM
Post# of 154888
Looks like another monoclonal is advancing for MS
Quote from Motley Fool 11/10:
What happened
Shares of biopharmaceutical company TG Therapeutics (TGTX 63.37%) climbed 63.37% on Thursday. The stock rose more than $3 on Thursday after closing on Wednesday at $5.16. It opened on Thursday at $5.83, and shortly before 2 p.m. ET jumped to a daily high of $8.44 before closing at $8.43. The stock has a 52-week low of $3.48 and a 52-week high of $33.87. The stock is down more than 55% so far this year.
So what
TG Therapeutics focuses on therapies to treat B-cell diseases. The company released its third-quarter earnings before the market opened on Thursday, but the rocket ship move upward had little to do with the company's financials and a lot to do with an announcement regarding its lead therapy, Ublituximab, a monoclonal antibody, to treat relapsed multiple sclerosis.
Quote from Motley Fool 11/10:
What happened
Shares of biopharmaceutical company TG Therapeutics (TGTX 63.37%) climbed 63.37% on Thursday. The stock rose more than $3 on Thursday after closing on Wednesday at $5.16. It opened on Thursday at $5.83, and shortly before 2 p.m. ET jumped to a daily high of $8.44 before closing at $8.43. The stock has a 52-week low of $3.48 and a 52-week high of $33.87. The stock is down more than 55% so far this year.
So what
TG Therapeutics focuses on therapies to treat B-cell diseases. The company released its third-quarter earnings before the market opened on Thursday, but the rocket ship move upward had little to do with the company's financials and a lot to do with an announcement regarding its lead therapy, Ublituximab, a monoclonal antibody, to treat relapsed multiple sclerosis.
(4)
(0)
